Why the latest Signatera study matters for Natera (NTRA) shareholders
Natera (NTRA) is back in focus after publishing new Clinical Cancer Research data on its Signatera test, showing how older women with early stage ER+/HER2- breast cancer might be treated with endocrine therapy alone.
The prospective study followed women aged 70 and above who chose to skip surgery and receive primary endocrine therapy, with Signatera used regularly alongside imaging and physician assessments to track molecular residual disease and inform care decisions.
See our latest analysis for Natera.
The new Signatera data lands after a volatile stretch for Natera, with the share price at US$207.98, a 7 day share price return of 13.87% and a 90 day share price return decline of 9.12%, alongside a 1 year total shareholder return of 55.36% and a 3 year total shareholder return of about 3x. This combination of metrics suggests that recent momentum has cooled compared with the longer term record.
If this kind of healthcare technology story interests you, it could be worth widening your search to other potential opportunities using the 36 healthcare AI stocks
With Natera trading at US$207.98, carrying a value score of 4 and flagged as trading below some intrinsic estimates, the real question is whether you are seeing a genuine mispricing or a market that is already factoring in future growth.
Most Popular Narrative: 20.2% Undervalued
On the most followed narrative, Natera’s fair value of $260.65 sits well above the $207.98 last close, putting a lot of weight on long term execution.
Investment in new product launches (e.g., Fetal Focus NIPT, Signatera Genome, AI-based biomarkers) and a robust R&D pipeline positions Natera to capture growth from long-term trends in personalized medicine and early detection, underpinning future revenue expansion.
Curious what earnings, revenue growth, and margin profile are baked into that gap between price and fair value? The narrative leans on bold compounding assumptions and premium future multiples that many investors will want to scrutinize closely.
Result: Fair Value of $260.65 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, there are clear pressure points here, including ongoing net losses of $208.16m and heavy R&D and SG&A spend that could delay any path to profitability.
Find out about the key risks to this Natera narrative.
Next Steps
With the story so mixed, it makes sense to look at the full picture yourself and act while sentiment is still shifting. Start with the 3 key rewards.
Looking for more investment ideas?
If Natera has caught your attention, do not stop here, widen your watchlist now so you are not relying on a single story to shape your returns.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it.
Discover if Natera might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com